GLOBUS MEDICAL, INC.
In the published model solve dated 2026-Q2, anchored at $82.97, GLOBUS MEDICAL, INC. (GMED) is priced for +17.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 29, 2026 from SEC EDGAR filings.
• Globus Medical is the spine business that owns its own robot: the Excelsius navigation and robotics platform pulls implant sales through every system it places, and the company describes offering ⟦flexibility to customers for our capital equipment within our Excelsius ecosystem by offering capital sales and leasing arrangements⟧ [Source: GMED FY2026 10-K]. • The biggest specific risk is the combination of integration and reimbursement: management's own filing warns the NuVasive and Nevro merge
Is GMED overvalued? See what's priced in →
584 institutional managers reported holding GMED in 13F filings for the quarter ended 2026-03-31. Together they hold about 77% of the company; the top 10 hold 35%. 93 opened new positions that quarter. Held by Vanguard Group, BlackRock, Janus Henderson, among others. On the short side, 5.5M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (3.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GMED's share count grew 34.8% over the past five years even with $530.73M spent on repurchases. It pays no dividend. Cash returned over the past three years: $386.24M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at GMED over the trailing three years. Absence is a fact about the company, not a signal. 10 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GMED's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -5.0% | -6.9% |
| 2023-11-08 | -1.4% | +18.6% |
| 2024-02-22 | +2.2% | -8.8% |
| 2024-05-08 | +22.8% | +12.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GMED's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-06-04 (items 5.02, 5.07, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-03-23 (items 5.02, 7.01, 9.01); 2026-02-24 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 29, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.